Your session is about to expire
← Back to Search
ANC-501 for Major Depressive Disorder
Phase 2
Waitlist Available
Research Sponsored by Ancora Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) up to day 112
Awards & highlights
No Placebo-Only Group
Summary
This trial will test a new drug for safety and effectiveness in people with major depression.
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline (day 1) up to day 112
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) up to day 112
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mental Depression
Treatment-emergent Adverse Events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ANC-501Experimental Treatment1 Intervention
50 mg/day
Find a Location
Who is running the clinical trial?
Ancora Bio, Inc.Lead Sponsor
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.Lead Sponsor
Phil Perera, MDStudy DirectorAncora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a history of bipolar disorder, schizophrenia, or schizoaffective disorder.Your current antidepressant medication is not working for you, even after trying different doses or making changes to the treatment plan.Your depression symptoms are severe, with a score of 28 or higher on a mood assessment test.You have tried at least two different treatments for your condition for at least 6 weeks each, but none of them have worked well enough.
Research Study Groups:
This trial has the following groups:- Group 1: ANC-501
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger